{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-033356","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2023-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.097825+00:00","generated_at":"2026-06-10T11:20:47.115632+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mangoceuticals enters consulting & amended services agreements with related party Epiq Scripts","bullets":["Engaged Epiq Scripts for global pharmacy consulting outside US; $65K upfront plus per-pill declining fees over 5 years (amounts redacted).","Amended MSA: added right of first negotiation/refusal for new jurisdictions and a 1% non-use fee on gross sales if services transferred.","Epiq Scripts is 51% owned by CEO Jacob D. Cohen; the agreements are related-party transactions.","No consulting payments until first commercial sale outside US; no immediate revenue impact expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-033356","json":"https://secwatch.observer/filing/0001493152-23-033356.json","markdown":"https://secwatch.observer/filing/0001493152-23-033356.md","text":"https://secwatch.observer/filing/0001493152-23-033356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315223033356/0001493152-23-033356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315223033356/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T11:20:47.115632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33ef38619ed40d789678f1bbad0e84842ca1f38f","claim":"MANGOCEUTICALS, INC. entered into Consulting Agreement with Epiq Scripts, LLC (effective 2023-09-15).","evidence_excerpt":"On September 15, 2023, Mangoceuticals, Inc. (the \" Company \", \" we \" and \" us \") entered into (1) a Consulting Agreement (the \" Consulting Agreement \") with Epiq Scripts, LLC (\" Epiq Scripts \")","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938046/000149315223033356/0001493152-23-033356-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Epiq Scripts, LLC"},{"label":"Effective","value":"2023-09-15"}],"fact_type":"material_agreement"},{"claim_id":"42cfe5e947e9186f113dfd27a39f77ee712c0fe7","claim":"MANGOCEUTICALS, INC. amended First Addendum to Master Services Agreement with Epiq Scripts, LLC (effective 2023-09-15).","evidence_excerpt":"and (2) a First Addendum to Master Services Agreement with Epiq Scripts (the \" First Amendment \"), which amended that certain Master Services Agreement dated September 1, 2022, by and between the Company and Epiq Scripts (the \" MSA \")","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938046/000149315223033356/0001493152-23-033356-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Epiq Scripts, LLC"},{"label":"Effective","value":"2023-09-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}